Methyldopa, an antihypertensive medication, was first patented in 1957. [1]
When does Methyldopa patent protection end?
Patents for methyldopa have long expired. The original patent, filed in 1957, would have had a typical term of 17 years. [1] This means patent protection for methyldopa concluded decades ago, allowing for the development of generic versions.
Who manufactures Methyldopa today?
Following patent expiry, various pharmaceutical companies have manufactured and marketed generic versions of methyldopa. Specific manufacturers can vary by region and over time. [2]
What are the clinical uses of Methyldopa?
Methyldopa is primarily used to treat hypertension, particularly in pregnant individuals where it is considered a preferred option for managing high blood pressure. [3] It works by relaxing blood vessels, which lowers blood pressure.
What is the mechanism of action for Methyldopa?
Methyldopa is a prodrug that is converted in the brain to alpha-methylnorepinephrine. This substance then stimulates alpha-adrenergic receptors in the brainstem, leading to a decrease in sympathetic outflow and a reduction in blood pressure. [4]
Are there alternative treatments for hypertension in pregnancy?
While methyldopa is a common choice, other antihypertensive medications may be considered for managing hypertension in pregnancy, depending on individual patient factors and clinical guidelines. [3]
---
Sources
1. https://www.drugpatentwatch.com/drug/methyldopa
2. https://www.drugpatentwatch.com/drug/methyldopa/manufacturers
3. American College of Obstetricians and Gynecologists. (2013). Gestational Hypertension and Preeclampsia. Obstetrics & Gynecology, 122(4), 894–897.
4. Lowenstein, J. (1987). Alpha-methyldopa. Hypertension, 9(6 Pt 2), II130–II134.